MOLN
Molecular Partners AG ADR
NASDAQ: MOLN · HEALTHCARE · BIOTECHNOLOGY
$4.23
-4.94% today
Updated 2026-04-30
Market cap
$162.74M
P/E ratio
—
P/S ratio
158.42x
EPS (TTM)
$-2.10
Dividend yield
—
52W range
$3 – $5
Volume
0.0M
Molecular Partners AG ADR (MOLN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-55.50%
ROA
-26.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $32.42M | $7.14M | 96.23% | 21.95% | 22.03% |
| 2014 | $26.63M | $-2.28M | 99.36% | 6.91% | -8.57% |
| 2015 | $29.12M | $-148823.00 | 96.00% | -7.62% | -0.51% |
| 2016 | $23.04M | $-18.61M | 36.76% | -84.57% | -80.78% |
| 2017 | $20.02M | $-25.43M | 10.96% | -129.12% | -127.05% |
| 2018 | $10.36M | $-37.04M | -50.67% | -361.27% | -357.66% |
| 2019 | $20.38M | $-36.29M | -113.40% | -179.86% | -178.03% |
| 2020 | $9.34M | $-62.76M | -500.12% | -624.21% | -671.70% |
| 2021 | $9.33M | $-63.78M | -497.19% | -679.72% | -683.65% |
| 2022 | $189.56M | $117.85M | 73.23% | 61.52% | 62.17% |
| 2023 | $7.04M | $-61.98M | -579.80% | -868.26% | -880.70% |
| 2024 | $4.97M | $-54.04M | -855.81% | -1,231.73% | -1,087.38% |
| 2025 | $0.00 | $-61.65M | — | — | — |